Stanley C. Erck

2017

In 2017, Stanley C. Erck earned a total compensation of $2.8M as President, CEO and Interim CFO at Novavax, a 29% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$383,760
Option Awards$1,753,125
Salary$624,000
Other$10,800
Total$2,771,685

Erck received $1.8M in option awards, accounting for 63% of the total pay in 2017.

Erck also received $383.8K in non-equity incentive plan, $624K in salary and $10.8K in other compensation.

Rankings

In 2017, Stanley C. Erck's compensation ranked 3,959th out of 14,666 executives tracked by ExecPay. In other words, Erck earned more than 73.0% of executives.

ClassificationRankingPercentile
All
3,959
out of 14,666
73rd
Division
Manufacturing
1,386
out of 5,772
76th
Major group
Chemicals And Allied Products
398
out of 2,075
81st
Industry group
Drugs
307
out of 1,731
82nd
Industry
Biological Products, Except Diagnostic Substances
56
out of 313
82nd
Source: SEC filing on April 30, 2018.

Erck's colleagues

We found four more compensation records of executives who worked with Stanley C. Erck at Novavax in 2017.

2017

Gregory Glenn

Novavax

President, Research and Development

2017

John Trizzino

Novavax

SVP, Commercial Operations

2017

John Herrmann

Novavax

General Counsel

2017

Barclay Phillips

Novavax

Chief Financial Officer

News

In-depth

You may also like